{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:10:38Z","timestamp":1791846638927,"version":"4.3.4"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1097\/js9.0000000000001044","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T17:01:25Z","timestamp":1713286885000},"page":"1894-1895","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Celebrating a breakthrough: FDA endorses encorafenib plus binimetinib alongside two companion diagnostics for BRAV600E mutant metastatic non-small cell lung cancer"],"prefix":"10.1097","volume":"110","author":[{"given":"Haleema Qayyum","family":"Abbasi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ayub Medical College, Abbottabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik Olatunde","family":"Oduoye","sequence":"additional","affiliation":[{"name":"Department of Medical Research Circle, Bukavu, Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4]]},"reference":[{"key":"R1-20250824","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Future Oncol"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12967-019-2036-7","article-title":"The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients","volume":"17","author":"Lin","year":"2019","journal-title":"J Transl Med"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2217\/fon-2021-1250","article-title":"Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design","volume":"18","author":"Riely","year":"2022","journal-title":"Future Oncol"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, Open-label study of encorafenib plus binimetinib in patients with BRAF V600-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J Clin Oncol"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/cancers13040804","article-title":"Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on the treatment of the most important actionable oncogenic driver alterations","volume":"13","author":"K\u00f6nig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"20363613231204798","DOI":"10.1177\/20363613231204798","article-title":"Advancing precision oncology in metastatic colorectal cancer: the food and drug administration approval of foundation one liquid CDx as a companion diagnostic a correspondence","volume":"15","author":"Shahnoor","year":"2023","journal-title":"Rare Tumors"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"102550","DOI":"10.1016\/j.tmaid.2023.102550","article-title":"mRNA vaccines as an armor to combat infectious diseases","volume":"52","author":"Priyanka","year":"2023","journal-title":"Travel Med Infect Dis"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:01:56Z","timestamp":1756062116000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001044","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"2023-11-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}